Description |
A cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µ M, 19.8 µ M, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µ M. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo. |
Reference |
1. Kunath, T., et al. Development 2007, 134, 2895
2. Stavridis, M.P., et al. Development 2007, 134, 2889
3. Zaragosi, L.E., et al. Stem Cells 2006, 24, 2412
4. St. Bernard, R., et al. Endocrinology 2005, 146, 1145
5. Koziczak, M., et al. Oncogene 2004, 23, 3501
6. Trudel, S., et al. Blood 2004, 103, 3521, 7. Skaper, S.D., et al. J. Neurochem. 2000, 75, 1520
8. Mohammadi, M., et al. EMBO J. 1998, 17, 5896. |